Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Roesch

Showing results (21-30 of 65) with videos related to

Pageof 7
Sort By:
Nuclear Medicine and Molecular Imaging|January 23, 2024
[<sup>177</sup>Lu]Lu-DOTAGA.Glu.(FAPi)<sub>2</sub> Radionuclide Therapy: a New Treatment Option for Patients with Glioblastoma MultiformeSanjana Ballal, Madhav P Yadav, Shobhana Raju, et al.
Chemmedchem|July 10, 2009
Ex vivo and in vivo evaluation of [18F]PR04.MZ in rodents: a selective dopamine transporter imaging agentPatrick J Riss, Fabian Debus, René Hummerich, et al.
Chemmedchem|September 11, 2010
The DAT ligand [(18)F]PR17.MZ mirrors the in vivo pharmacokinetic profile of [(11)C]cocaine with significantly improved monoamine transporter selectivityPatrick J Riss, Markus Piel, Vanessa Bockhart, et al.
Clinical Nuclear Medicine|November 6, 2024
Exploring the FAP-Targeted Therapeutics for Adrenocortical Carcinoma: Choosing the Right TrackSejal Chopra, Rama Walia, Komalpreet Kaur, et al.
Journal of the American Society of Nephrology : JASN|January 20, 2006
Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic ratsTobias Odenwald, Kumiko Nakagawa, Charlotte Hadtstein, et al.
Pharmaceuticals (Basel, Switzerland)|December 28, 2021
First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [<sup>177</sup>Lu]Lu-DOTA.SA.FAPi and [<sup>177</sup>Lu]Lu-DOTAGA.(SA.FAPi)<sub>2</sub>Sanjana Ballal, Madhav Prasad Yadav, Euy Sung Moon, et al.
Nuclear Medicine and Biology|August 6, 2008
Validation of (68)Ge/(68)Ga generator processing by chemical purification for routine clinical application of (68)Ga-DOTATOCMattia Asti, Giovanni De Pietri, Alessandro Fraternali, et al.
EJNMMI Research|June 25, 2026
Long-term outcomes in medullary thyroid cancer patients treated with [<sup>177</sup>Lu]Lu-DOTAGA.FAPi dimer therapySanjana Ballal, G B Priyanka, Madhav Prasad Yadav, et al.
EJNMMI Research|November 30, 2019
Biodistribution and post-therapy dosimetric analysis of [<sup>177</sup>Lu]Lu-DOTA<sup>ZOL</sup> in patients with osteoblastic metastases: first resultsAmbreen Khawar, Elisabeth Eppard, Frank Roesch, et al.
Clinical Nuclear Medicine|August 1, 2024
68 Ga-DOTA.SA.FAPi PET in Response Assessment After 177 Lu-Microspheres Selective Intra-arterial Radionuclide Therapy for Unresectable Hepatocellular CarcinomaSejal Chopra, Yamini Mathur, Frank Roesch, et al.
Pageof 7

Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
Nuclear Medicine and Molecular Imaging|January 23, 2024
[<sup>177</sup>Lu]Lu-DOTAGA.Glu.(FAPi)<sub>2</sub> Radionuclide Therapy: a New Treatment Option for Patients with Glioblastoma MultiformeSanjana Ballal, Madhav P Yadav, Shobhana Raju, et al.
Chemmedchem|July 10, 2009
Ex vivo and in vivo evaluation of [18F]PR04.MZ in rodents: a selective dopamine transporter imaging agentPatrick J Riss, Fabian Debus, René Hummerich, et al.
Chemmedchem|September 11, 2010
The DAT ligand [(18)F]PR17.MZ mirrors the in vivo pharmacokinetic profile of [(11)C]cocaine with significantly improved monoamine transporter selectivityPatrick J Riss, Markus Piel, Vanessa Bockhart, et al.
Clinical Nuclear Medicine|November 6, 2024
Exploring the FAP-Targeted Therapeutics for Adrenocortical Carcinoma: Choosing the Right TrackSejal Chopra, Rama Walia, Komalpreet Kaur, et al.
Journal of the American Society of Nephrology : JASN|January 20, 2006
Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic ratsTobias Odenwald, Kumiko Nakagawa, Charlotte Hadtstein, et al.
Pharmaceuticals (Basel, Switzerland)|December 28, 2021
First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [<sup>177</sup>Lu]Lu-DOTA.SA.FAPi and [<sup>177</sup>Lu]Lu-DOTAGA.(SA.FAPi)<sub>2</sub>Sanjana Ballal, Madhav Prasad Yadav, Euy Sung Moon, et al.
Nuclear Medicine and Biology|August 6, 2008
Validation of (68)Ge/(68)Ga generator processing by chemical purification for routine clinical application of (68)Ga-DOTATOCMattia Asti, Giovanni De Pietri, Alessandro Fraternali, et al.
EJNMMI Research|June 25, 2026
Long-term outcomes in medullary thyroid cancer patients treated with [<sup>177</sup>Lu]Lu-DOTAGA.FAPi dimer therapySanjana Ballal, G B Priyanka, Madhav Prasad Yadav, et al.
EJNMMI Research|November 30, 2019
Biodistribution and post-therapy dosimetric analysis of [<sup>177</sup>Lu]Lu-DOTA<sup>ZOL</sup> in patients with osteoblastic metastases: first resultsAmbreen Khawar, Elisabeth Eppard, Frank Roesch, et al.
Clinical Nuclear Medicine|August 1, 2024
68 Ga-DOTA.SA.FAPi PET in Response Assessment After 177 Lu-Microspheres Selective Intra-arterial Radionuclide Therapy for Unresectable Hepatocellular CarcinomaSejal Chopra, Yamini Mathur, Frank Roesch, et al.
Pageof 7